New pill takes on deadly leukemia in major trial
NCT ID NCT05586074
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HEC73543 (Clifutinib) against standard chemotherapy in 324 adults with a specific type of acute myeloid leukemia (FLT3-ITD) that has come back or not responded to first treatment. The goal is to see if the new drug helps people live longer and achieve remission. Participants are randomly assigned to receive either the new drug or chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, ACUTE MYELOID (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital,College of Medicine,Zhejiang University
RECRUITINGHanzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••